Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
- PMID: 35869162
- PMCID: PMC9307428
- DOI: 10.1007/s00467-022-05692-1
Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
Abstract
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated immune disorder in children, associated with Epstein-Barr virus (EBV) infection or malignancies. In severe forms, HLH presents with signs and symptoms of hyperinflammation that progress to life-threatening multiorgan failure. Intervention with an extracorporeal immunomodulatory treatment utilizing a selective cytopheretic device (SCD) could be beneficial. The SCD with regional citrate anticoagulation selectively binds the most highly activated circulating neutrophils and monocytes and deactivates them before release to the systemic circulation. Multiple clinical studies, including a multicenter study in children, demonstrate SCD therapy attenuates hyperinflammation, resolves ongoing tissue injury and allows progression to functional organ recovery. We report the first case of SCD therapy in a patient with HLH and multi-organ failure.
Case diagnosis/treatment: A previously healthy 22-month-old toddler presented with fever, abdominal distension, organomegaly, pancytopenia, and signs of hyperinflammation. EBV PCR returned at > 25 million copies. The clinical and laboratory pictures were consistent with systemic EBV-positive T-cell lymphoma with symptoms secondary to HLH. The patient met inclusion criteria for an ongoing study of integration of the SCD with a continuous kidney replacement therapy (CKRT) as part of standard of care. The patient received CKRT-SCD for 4 days with normalization of serum markers of sepsis and inflammation. The patient underwent hematopoietic stem cell transplantation 52 days after presentation and has engrafted with normal kidney function 8 months later.
Conclusions: SCD treatment resulted in improvement of poor tissue perfusion reflected by rapid decline in serum lactate levels, lessened systemic capillary leak with discontinuation of vasoactive agents, and repair and recovery of lung and kidney function with extubation and removal of hemodialysis support.
Keywords: Case Report; Child; Extracorporeal Immunomodulation; Hemophagocytic Lymphohistiocytosis.
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Figures
Similar articles
-
Severe hemorrhagic coagulopathy with hemophagocytic lymphohistiocytosis secondary to Epstein-Barr virus-associated T-cell lymphoproliferative disorder.Pediatr Crit Care Med. 2013 May;14(4):e176-81. doi: 10.1097/PCC.0b013e3182720f94. Pediatr Crit Care Med. 2013. PMID: 23439459
-
Hemophagocytic Lymphohistiocytosis in Renal Transplant Recipients: A 2-Case Report.Transplant Proc. 2020 Jun;52(5):1566-1569. doi: 10.1016/j.transproceed.2020.02.047. Epub 2020 May 8. Transplant Proc. 2020. PMID: 32389490
-
Clinical laboratory Analysis of EB Virus Associated Hemophagocytic Lymphohistiocytosis in Children.Altern Ther Health Med. 2024 May;30(5):148-154. Altern Ther Health Med. 2024. PMID: 38639627
-
The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder.Int J Clin Exp Pathol. 2014 Aug 15;7(9):5738-49. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25337215 Free PMC article. Review.
-
Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.Br J Haematol. 2022 Jan;196(1):31-44. doi: 10.1111/bjh.17638. Epub 2021 Jun 24. Br J Haematol. 2022. PMID: 34169507 Review.
Cited by
-
Management dilemma in choosing evolving treatments in neutropenic septic shock.Pediatr Nephrol. 2025 Jun 21. doi: 10.1007/s00467-025-06798-y. Online ahead of print. Pediatr Nephrol. 2025. PMID: 40542849
-
Immunomodulatory effects of a cell processing device to ameliorate dysregulated hyperinflammatory disease states.Sci Rep. 2024 Jun 3;14(1):12747. doi: 10.1038/s41598-024-63121-9. Sci Rep. 2024. PMID: 38830924 Free PMC article.
-
Selective Cytopheretic Device Use in Continuous Kidney Replacement Therapy in Children: A Cohort Study With a Historical Comparator.Kidney Med. 2024 Feb 15;6(4):100792. doi: 10.1016/j.xkme.2024.100792. eCollection 2024 Apr. Kidney Med. 2024. PMID: 38576525 Free PMC article.
-
The Impact of the Selective Cytopheretic Device on Neutrophil-to-Lymphocyte Ratios and Hematological Parameters in Acute Kidney Injury: A Pooled Analysis.Nephron. 2025 May 30:1-13. doi: 10.1159/000546528. Online ahead of print. Nephron. 2025. PMID: 40451159 Free PMC article.
-
Increasing Eligibility to Transplant Through the Selective Cytopheretic Device: A Review of Case Reports Across Multiple Clinical Conditions.Transplant Direct. 2024 May 16;10(6):e1627. doi: 10.1097/TXD.0000000000001627. eCollection 2024 Jun. Transplant Direct. 2024. PMID: 38769980 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous